Aurobindo Pharma Share Price (AUROPHARMA)
Check the latest share price of Aurobindo Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 04 Jul 2025
NSE
Aurobindo Pharma Stock Performance
Get live Aurobindo Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,158.6Day's Price Range₹1,19752 Week's Low
52 Week's High
₹1,01052-Week Price Range₹1,592
| Returns % | |
| 1 Month Return | + 2.74 % |
| 3 Month Return | + 8.89 % |
| 1 Year Return | -8.61 % |
| 3 Year Return | + 123.34 % |
| 5 Year Return | + 55.14 % |
| Market Stats | |
| Previous Close | ₹1,156.10 |
| Open | ₹1,160.10 |
| Volume | 19.33L |
| Upper Circuit | ₹1,271.70 |
| Lower Circuit | ₹1,040.50 |
Aurobindo Pharma Fundamentals & Key Indicators
Check Aurobindo Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹69,802.87 Cr
Return on Equity (ROE)
10.35
PE Ratio (TTM)
19.92
Return on capital employed (ROCE)
11.74
Industry PE ratio
54.65
Beta (LTM)
0.85
P/B Ratio
3.24
Dividend Yield
0.41
PEG Ratio
3.5
Quarterly Earnings Growth YOY
-0.5
EPS (TTM)
54.09
Sector
Pharmaceuticals
Book Value
509.35
Technical Analysis
Bullish
View Technical Analysis
How to invest in Aurobindo Pharma?
Investing in Aurobindo Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Aurobindo Pharma or AUROPHARMA on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Aurobindo Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Aurobindo Pharma with just a few clicks!
Aurobindo Pharma Stock's Interest Amongst Investors
Aurobindo Pharma Valuation
Track how Aurobindo Pharma P/E has moved over time to understand its valuation trends.
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (19.92x)
July 4, 2025
Industry (54.65x)
July 4, 2025
Highest (27.59x)
December 21, 2023
Today’s Price to Earnings Ratio: 19.92x
Aurobindo Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Aurobindo Pharma.
based on 26 analysts
80.77%
Buy
3.85%
Hold
15.38%
Sell
80.77% of analysts recommend a 'BUY' rating for Aurobindo Pharma. Average target price of ₹1393.23
Source: S&P Global Market Intelligence
Aurobindo Pharma Share Price Target
Get share price movements and forecasts by analysts on Aurobindo Pharma.
Aurobindo Pharma price forecast by 26 analysts
Upside of16.95%
High
₹1930
Target
₹1393.23
Low
₹1100
Aurobindo Pharma target price ₹1393.23, a slight upside of 16.95% compared to current price of ₹1191.3. According to 26 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:27.38%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:43.46%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Financial Results
Get the annual and quarterly financial summary of Aurobindo Pharma, including revenue, profit, loss and more.
Indices Featuring Aurobindo Pharma Stock
Check stock indices that include Aurobindo Pharma.
Aurobindo Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Aurobindo Pharma.
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -0.58% since last year same period to ₹903.47Cr in the Q4 2024-2025. On a quarterly growth basis, Aurobindo Pharma Ltd has generated 6.82% jump in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends February,2024
In the quarter ending December 2023, Aurobindo Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.38%.
Read More about Dividends
Aurobindo Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Aurobindo Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 15.33% | 0.00 | |
| Mutual Funds | 18.21% | 0.00 | |
| Retail Investors | 6.61% | 0.00 | |
| Others | 8.03% | 0.00 |
Aurobindo Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Aurobindo Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 69,802.87 | 11.03% | 0.56 | 3,168 | 29,001 | |
| BUY | 14,004.54 | -3.99% | 0.52 | 413 | 2,013 | |
| HOLD | 1,00,724.02 | 35.17% | 0.64 | 3,854 | 19,547 | |
| BUY | 73,811.88 | 24.18% | 0.53 | NA | NA | |
| BUY | 55,627.86 | 24.29% | 0.56 | 927 | 3,749 |
Aurobindo Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Aurobindo Pharma.
Aurobindo Pharma Reports Strong Quarterly Earnings - 04 Jul, 2025
Aurobindo Pharma's Q4 revenue increased to Rs 8,382.12 Crore, with a net profit of Rs 935.02 Crore. The company shows overall growth in 2025.Aurobindo Pharma's Subsidiary Gains Approval for Dazublys - 02 Jul, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received European Commission approval for Dazublys, a trastuzumab biosimilar for HER2-positive cancers, marking its third EMA-approved biosimilar in 2025.Aurobindo Resumes Penicillin-G Production After Fire - 30 Jun, 2025
Aurobindo Pharma's subsidiary, Lyfius Pharma, has resumed Penicillin-G production at its Kakinada plant after receiving approval from the Andhra Pradesh Pollution Control Board, following a fire incident in April.Aurobindo Pharma Recalls Gentamicin Injection in U.S. - 28 Jun, 2025
Aurobindo Pharma's subsidiary, Eugia US LLC, is recalling 48,000 vials of Gentamicin Injection due to failed stability specifications. The recall is voluntary and was initiated on May 29.Aurobindo Pharma Recalls Pain Relief Medication - 27 Jun, 2025
Aurobindo Pharma is recalling 4,608 bottles of Acetaminophen Tablets in the U.S. due to manufacturing issues and confirmed consumer complaints about tablet discoloration. The recall is classified as Class II by the FDA, indicating potential temporary health consequences.CuraTeQ Secures UK Approval for Dyrupeg Biosimilar - 24 Jun, 2025
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received marketing authorization from the UK's MHRA for Dyrupeg, enhancing access to affordable cancer treatments. This marks the third biosimilar approval for CuraTeQ in the UK.Aurobindo Pharma Faces Tariff Concerns Amid Growth Plans - 21 Jun, 2025
Aurobindo Pharma, a leading generic drug manufacturer, is vulnerable to potential US tariffs due to its significant revenue exposure. Despite this, the company is expanding its US presence with a new subsidiary and focusing on biosimilars, targeting a $50 billion market opportunity.Nuvama Bullish on Aurobindo Pharma's Growth Potential - 20 Jun, 2025
Nuvama Institutional Equities maintains a Buy rating on Aurobindo Pharma, projecting a 15% profit CAGR through FY27, driven by new product launches and capacity expansions. The stock is seen as undervalued, trading at a discount to historical averages, with key growth triggers anticipated in the coming years.Aurobindo Pharma Faces Continued Decline - 17 Jun, 2025
Aurobindo Pharma Ltd has declined for the fifth consecutive session, trading at Rs 1109.7, down 3.12%. The stock has lost 10.7% over the past year, underperforming the NIFTY and Nifty Pharma index. Additionally, it has dropped 7.98% in the last month, with trading volume below average.Aurobindo Pharma Expands US Operations with New Subsidiary - 16 Jun, 2025
Aurobindo Pharma's US subsidiary has established Cresedemo Pharma LLC to enhance its pharmaceutical product offerings in the USA. Despite a slight profit decline, net sales increased significantly.Aurobindo Pharma Named Top Stock Pick by Axis - 05 Jun, 2025
Axis Securities has identified Aurobindo Pharma as a top stock pick, maintaining a Buy rating with a target price of Rs 1,500, indicating a potential upside of 32%.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 3 quarters, 817.38 Cr → 903.47 Cr (in ₹), with an average increase of 4.9% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 11 quarters, 5.79K Cr → 8.51K Cr (in ₹), with an average increase of 3.7% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 17.81% to 18.21% in Mar 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, AUROPHARMA stock has moved up by 5.0%
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.9% return, outperforming this stock by 9.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 49.2% return, outperforming this stock by 57.8%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 16.29% to 15.33% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.69% to 6.61% in Mar 2025 quarter
About Aurobindo Pharma
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹8,381.12Cr as on March 2025 (Q4 FY25)
Net Profit: ₹902.83Cr as on March 2025 (Q4 FY25)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | K Ragunathan |
| E-voting on shares | Click here to vote |
Mutual Funds that own Aurobindo Pharma
Check out the Mutual Funds with significant holdings in Aurobindo Pharma.
FAQs
What is Aurobindo Pharma share price today?
Aurobindo Pharma share price today stands at ₹1191.3, Open: ₹1160.1, Previous Close: ₹1156.1, High: ₹1197, Low: ₹1158.6, 52 Week High: ₹1592, 52 Week Low: ₹1010.
What is today's traded volume of Aurobindo Pharma?
Today's traded volume of Aurobindo Pharma is 19.33L. Which means that 19.33L shares of Aurobindo Pharma were bought and sold on the stock market during today's trading session.
What is Aurobindo Pharma's market cap today?
Today's market capitalisation of Aurobindo Pharma is ₹69,802.87 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Aurobindo Pharma?
Aurobindo Pharma’s 52 week high is ₹1592 and 52 week low is ₹1010. The current share price of Aurobindo Pharma is ₹1191.3, which is -25.17% down from its 52 week high and 17.95% up from its 52 week low.